© 2021 MJH Life Sciences and Urology Times. All rights reserved.
© 2021 MJH Life Sciences™ and Urology Times. All rights reserved.
March 05, 2021
In the phase 2 SWOG 1500 study, cabozantinib (Cabometyx) significantly improved progression-free survival versus sunitinib (Sutent) in patients with metastatic papillary renal cell carcinoma.
March 01, 2021
Darolutamide is currently approved for the treatment of patients with nonmetastatic castration-resistant prostate cancer.
February 25, 2021
The immunotherapy/TKI combination significantly improved overall survival versus sunitinib.
February 24, 2021
Papillary renal cell carcinoma (RCC) is a rare malignancy, accounting for 15% of all RCC cases.
February 17, 2021
“These findings support the importance of genomic testing to identify patients eligible to consider olaparib treatment,” said Johann de Bono, MB CHB, PhD, MSC.
February 16, 2021
The FDA is scheduled to decide on a new drug application for tivozanib by March 31, 2021, for use in relapsed/refractory renal cell carcinoma.
February 15, 2021
The multikinase inhibitor showed significant intracranial and extracranial responses in patients with metastatic renal cell carcinoma and brain metastases.
The combination of the anti–PD-1 immunotherapy and the multikinase inhibitor also extended progression-free survival in the phase 3 KEYNOTE-581/CLEAR trial (Study 307).
February 14, 2021
Safety findings from the final analysis of the phase 3 ARAMIS trial showed that the androgen receptor inhibitor remained well tolerated with longer treatment.
The ongoing trial is enrolling patients at 62 locations in the United States and worldwide.